611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line
1-877-756-4090

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Health Sciences
Resources
Basic InformationLatest News
Small Trial Provides New Hope Against Parkinson's DiseaseInsomnia May Be in Your Genes'Miracle' Young Blood Infusion Treatments Unproven, Potentially Harmful: FDAPossible Parkinson's 'Pandemic' Looms: ReportScience Puzzling Out Differences in Gut Bacteria Around the World'Mind-Reading' AI Turns Thoughts Into Spoken WordsEat What You Want and Still Stay Slim? Thank Your GenesGood News, Bad News on Levodopa for Parkinson's DiseaseNature or Nurture? Twins Study Helps Sort Out Genes' Role in DiseaseBeing Bullied May Alter the Teen BrainFDA Warns Companies on Dangerous, Unapproved Stem Cell TreatmentsGene Tweaking Prevented Obesity in MiceApproach That New Gene Testing Kit With CautionResearch on Almost 2,000 Brains Brings Insight Into Mental IllnessRestoring Hair Growth on Scarred Skin? Mouse Study Could Show the WayParkinson's Gene Therapy Wires New Brain CircuitsNext for Disabling Back Pain? New Discs From Patients' Own CellsSkin 'Glow' Test Might Someday Spot Disease Risk EarlyComputer-Brain Link Helps 'Locked In' People Chat, Surf WebCould a Natural Protein Help Fight Obesity?Blood Test May One Day Help Track Concussion RecoveryThe Bigger the Brain, the Bigger the Tumor Risk?Gene Therapy for Parkinson's Symptoms Shows PromiseCould Same-Sex Couples Have Babies With Shared DNA? Study Hints It's PossibleMany Americans Curious, But Wary, About Gene TestingAHA: New Report Explores Genes Behind Congenital Heart DiseaseScientists Find 500 More Genes That Influence Blood PressureALS Affects the Mind, Not Just the BodyScientists Finally Get Around to Finding Procrastination's Home in the BrainGene 'Editing' in Dog Study Shows Promise for Kids With Muscular DystrophyGut Enzyme Could Help Solve U.S. Blood Shortages'Fat' Mouse Test Failure Yields New Obesity ClueIs Evolution of the Human Brain to Blame for Some Mental Disorders?Scientists Trace Link Between Head Injuries and Parkinson'sAHA: Scientists May Have Cleared Gene Therapy HurdleAlmost 1,300 Genes Seem Tied to Academic SuccessBrains May Be as Unique as Fingerprints'Heading' Soccer Balls May Be Bad for BalanceScientists Target Cellular 'Fountain of Youth' to Extend Mouse Life SpanThose At-Home DNA Tests Are an Imperfect ScienceScientists Spot Gene Linking Down Syndrome, Early Alzheimer'sMassive Study Finds Same Genes Drive Many Psychiatric ConditionsThyroid Cancer Survivors at Risk for Heart DiseaseBetter Diet, Bigger Brain?Primary Care Providers Have Mixed Views on Genetic TestsFDA Targets Clinics Offering Unapproved Stem Cell TherapiesRestless Legs Linked to Brain ChangesContact Sports May Alter the Brain, Scans SuggestJust One Concussion Could Raise Parkinson's RiskLove Your Hair Color? You Have Over 100 Genes to Thank.
Questions and AnswersLinksBook Reviews
Related Topics

Medical Disorders
Mental Disorders
Mental Health Professions

FDA Warns Companies on Dangerous, Unapproved Stem Cell Treatments

HealthDay News
by By E.J. Mundell
HealthDay Reporter
Updated: Dec 21st 2018

new article illustration

FRIDAY, Dec. 21, 2018 (HealthDay News) -- After infections tied to unapproved stem cell treatments sent 12 people to hospital this past year, the U.S. Food and Drug Administration on Thursday issued a stern warning about the products.

"The letters we're issuing today to manufacturers, health care providers and clinics around the country are a reminder that there's a clear line between appropriate development of these products and practices that sidestep important regulatory controls needed to protect patients," FDA Commissioner Dr. Scott Gottlieb said in a statement.

At issue are stem cell treatments -- so-called "cell-based regenerative medicine." Because stem cells have the potential to generate any type of cell, these treatments have long been marketed as a cure-all for a range of illnesses.

Hundreds of clinics touting the unapproved treatments have sprung up across the United States.

However, shoddy oversight may have led some hopeful patients to be seriously harmed, not helped, by these therapies, the FDA said.

In a report published Thursday, researchers at the U.S. Centers for Disease Control and Prevention say 12 stem cell therapy patients developed infections so severe they required hospitalization, although none died. Seven of the cases occurred in Texas, four in Florida and one in Arizona, according to a team led by CDC investigator Kiran Perkins.

Between February and September of 2018, these patients sought the treatments for a variety of complaints, including chronic pain, joint or back pain, rheumatoid arthritis or osteoarthritis, and rotator cuff tears.

But potentially deadly infections, such as E. coli or enterococcus, quickly set in within the patients' joints or bloodstreams.

One patient required hospitalization for 58 days, another for 35, Perkins' team reported Dec. 20 in the CDC journal Morbidity and Mortality Weekly Report.

The CDC investigators say that in one Texas clinic implicated in cases there, the Enterococcus cloacae bacterium was found in all six vials containing the stem cell product used. Similar results were found in vials tested at other implicated clinics.

However, the source of the infections cited in the new report seemed to be the point of manufacture, not the clinics themselves.

The products covered by the new warning were processed by Genetech, based in San Diego, and distributed by Yorba Linda, Ca.-based Liveyon. None of the stem cell products were "FDA-approved or lawfully marketed," the CDC researchers said. Liveyon issued a recall of the implicated products in October.

The CDC researchers stressed that umbilical cord blood -- often used as the source of transplanted stem cells -- is extremely difficult to sterilize.

"Umbilical cord blood cannot be decontaminated after collection because there are currently no validated processes for sterilization, so manufacture of derived products must be highly controlled to prevent distribution of contaminated products," Perkins' team noted.

However, despite repeated warnings, "many companies, clinics, and clinicians continue to market products from various sources as treatment for orthopedic, neurologic and rheumatologic conditions without FDA approval," the team said. That poses "serious potential risks to patients," they added.

The new FDA warning letter is targeted to Genetech and Liveyon. The FDA says that in June its inspectors assessed conditions at Genetech's plant and "documented evidence of significant deviations" from standard guidelines on safe manufacture.

"These deviations pose a significant risk that the products may be contaminated with microorganisms or have other serious product quality defects," the FDA said.

Gottlieb said the FDA announcement issued Thursday is a final warning to companies before tougher enforcement.

"Time is running out for firms to come into compliance during our period of enforcement discretion," he said. "We'll be increasing our oversight related to cell-based regenerative medicine as part of our comprehensive plan to promote beneficial innovation while protecting patients."

More information

There's more on stem cell therapy at the U.S. National Center for Biotechnology Information.